- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07244211
MAPT-Protokoll: Fixierungs- versus Endoprothesenchirurgische Behandlungen für Früherholung nach Hüftfraktur (FASTER-HIP) (FASTER-HIP)
Musculoskeletal Adaptive Platform Trial (MAPT): Fixierung versus Arthroplastik chirurgische Behandlungen für frühe Genesung nach Hüftfraktur (FASTER-HIP)
This study is an intervention domain of the Musculoskeletal Adaptive Platform Trial. The primary goal of this pragmatic, randomized, open-label, comparative effectiveness trial is to evaluate if arthroplasty is superior to internal fixation when used to treat minimally displaced femoral neck fractures in older adults ≥60 years old. We hypothesize that arthroplasty will reduce death, preserve ambulation, increase days alive and out of hospital, and improve health status compared to internal fixation within 4 months and 12 months from randomization.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The Musculoskeletal Adaptive Platform Trial (MAPT) is an adaptive platform trial protocol that enables the simultaneous evaluation of multiple interventions (i.e., intervention domains) within a consistent infrastructure. Each intervention being evaluated in the MAPT will have an intervention domain protocol that describes additional eligibility criteria, interventions, secondary outcomes, and statistical stopping rules. The overarching objective of the MAPT trial platform is to incrementally decrease decisional uncertainty and identify treatments that will optimize patient outcomes. The platform focuses on the comparative effectiveness of available treatment options.
Adult patients aged 60 years or older with a low-energy minimally displaced femoral neck fracture treated with surgery are eligible for the FASTER-HIP intervention domain. Nearly half of all elderly hip fractures are femoral neck fractures, and approximately 20% are minimally displaced. Internal fixation has remained the treatment of choice for these injuries because these fractures can be fixed in situ, and the surgical implants can be inserted with little surgical dissection. Patients treated with internal fixation experience high complication rates, with the pooled risk of reoperation and mortality each above 14%. Preliminary data have suggested arthroplasty for minimally displaced fractures may lead to better patient outcomes, including improved ambulation, fewer reoperations, and a lower risk of death compared to internal fixation. While the preliminary data supporting the use of arthroplasty for minimally displaced fractures is promising, the necessary evidence to make this practice change remains lacking.
FASTER-HIP is a pragmatic, randomized, open-label, comparative effectiveness trial comparing hip arthroplasty versus internal fixation for minimally displaced femoral neck fractures. Randomization in this domain occurs in a 1:1 ratio (hip arthroplasty:internal fixation). The primary outcome is a composite of death within 120 days, ambulation status at 120 days, and days alive and out of hospital within 120 days of randomization. The primary outcome will be hierarchically assessed using the Win ratio. Secondary outcomes include the same composite at 365 days, individual components of the composite, health-related quality of life (EQ-5D-5L), and pain scores during hospitalization.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Joseph Patterson, MD
- Telefonnummer: +13234426984
- E-Mail: OrthoTraumaResearch@med.usc.edu
Studienorte
-
-
-
Ottawa, Kanada, K1H 8L6
- Noch keine Rekrutierung
- The Ottawa Hospital
-
Kontakt:
- Bradley Meulenkamp, MD
- E-Mail: bmeulenkamp@toh.ca
-
Hauptermittler:
- Bradley Meulenkamp, MD
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6T 1Z4
- Rekrutierung
- University of British Columbia
-
Kontakt:
- Aresh Sepehri, MD
-
Kontakt:
- E-Mail: aresh.sepehri@vch.ca
-
Hauptermittler:
- Aresh Sephri, MD
-
Vancouver, British Columbia, Kanada
- Rekrutierung
- Fraser Health Authority
-
Kontakt:
- Darius Viskontas, MD
- Telefonnummer: 604-777-5577
- E-Mail: dariusviskontas@yahoo.ca
-
Kontakt:
- Telefonnummer: 604-777-5577
-
Hauptermittler:
- Darius Viskontas, MD
-
-
Ontario
-
London, Ontario, Kanada, N6A 5W9,
- Rekrutierung
- London Health Sciences Centre
-
Kontakt:
- Emil Schemitsch, MD
- E-Mail: emil.schemitsch@lhsc.on.ca
-
Hauptermittler:
- Emil Schemitsch, MD
-
-
-
-
-
Grålum, Norwegen, 1714
- Rekrutierung
- Sykehuset Østfold HF / Østfold Hospital Trust
-
Kontakt:
- Frede Frihagen, MD
-
Kontakt:
- E-Mail: Frede.Frihagen@so-hf.no
-
Hauptermittler:
- Frede Frihagen, MD
-
-
-
-
-
Barcelona, Spanien
- Noch keine Rekrutierung
- Hospital Universitari Vall d'Hebron
-
Kontakt:
- Carlos Alberto Piedra-Calle, MD
- E-Mail: carlosalberto.piedra@vallhebron.cat
-
Hauptermittler:
- Carlos Alberto Piedra-Calle, MD
-
Barcelona, Spanien
- Noch keine Rekrutierung
- Consorci Sanitari de l'Alt Penedès i Garraf (CSAPG)
-
Hauptermittler:
- Alfred Dealbert, MD
-
Kontakt:
- Alfred Dealbert Dealbert, MD
- E-Mail: adealbert@csapg.cat
-
Barcelona, Spanien, 08221
- Noch keine Rekrutierung
- Hospital Universitario Mutua de Terrassa
-
Kontakt:
- Pablo Castillon Bernal, MD
- E-Mail: pablocastillon@mutuaterrassa.es
-
Hauptermittler:
- Pablo Castillon Bernal, MD
-
Barcelona, Spanien
- Noch keine Rekrutierung
- FRCB-IDIBAPS (Hospital Clinic Barcelona)
-
Kontakt:
- Pilar Camacho, MD
- E-Mail: PCAMACHO@clinic.cat
-
Hauptermittler:
- Pilar Camacho, MD
-
-
-
-
California
-
Irvine, California, Vereinigte Staaten, 92660
- Rekrutierung
- University of California, Irvine
-
Hauptermittler:
- Gerard Slobogean, MD
-
Kontakt:
- Gerard Slobogean, MD
- Telefonnummer: 714-456-1699
- E-Mail: gsloboge@hs.uci.edu
-
Los Angeles, California, Vereinigte Staaten, 90048
- Rekrutierung
- Cedars-Sinai Medical Center
-
Hauptermittler:
- Carol Lin, MD
-
Kontakt:
- Carol Lin, MD
- E-Mail: carol.lin@cshs.org
-
Los Angeles, California, Vereinigte Staaten, 90033
- Rekrutierung
- University of Southern California
-
Hauptermittler:
- Joshua L Gary, MD
-
Kontakt:
- Joshua Gary, MD
- Telefonnummer: +13234426984
- E-Mail: OrthoTraumaResearch@med.usc.edu
-
Los Angeles, California, Vereinigte Staaten, 90033
- Rekrutierung
- Los Angeles General Medical Center
-
Hauptermittler:
- Joshua L Gary, MD
-
Kontakt:
- Joshua Gary, MD
- Telefonnummer: +13234426984
- E-Mail: OrthoTraumaResearch@med.usc.edu
-
San Francisco, California, Vereinigte Staaten, 94143
- Rekrutierung
- University of California San Francisco
-
Hauptermittler:
- Saam Morshed, MD
-
Kontakt:
- Saam Morshed, MD
- E-Mail: Saam.morshed@ucsf.edu
-
-
Florida
-
Miami, Florida, Vereinigte Staaten, 33146
- Noch keine Rekrutierung
- University of Miami
-
Kontakt:
- Giselle Hernandez, MD
- E-Mail: g.hernandez@med.miami.edu
-
Hauptermittler:
- Giselle Hernandez, MD
-
-
Indiana
-
Bloomington, Indiana, Vereinigte Staaten, 47405
- Rekrutierung
- Indiana University
-
Hauptermittler:
- Dillon O'Neill, MD
-
Kontakt:
- Dillon O'Neill, MD
- E-Mail: doneill5@iuhealth.org
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21201
- Rekrutierung
- University of Maryland, Baltimore - R Adams Cowley Shock Trauma Center
-
Hauptermittler:
- Mark Gage, MD
-
Kontakt:
- Mark Gage, MD
- E-Mail: mgage@som.umaryland.edu
-
Largo, Maryland, Vereinigte Staaten, 20774
- Rekrutierung
- University of Maryland Capital Region Health
-
Hauptermittler:
- Todd Jaeblon, MD
-
Kontakt:
- Todd Jaeblon, MD
- E-Mail: tjaeblon@som.umaryland.edu
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Noch keine Rekrutierung
- Beth Israel Deaconess Medical Center
-
Kontakt:
- Ishaq Ibrahim, MD
- E-Mail: ioibrahi@bidmc.harvard.edu
-
Hauptermittler:
- Ishaq Ibrahim, MD
-
Boston, Massachusetts, Vereinigte Staaten, 02115
- Rekrutierung
- Massachusetts General Brigham
-
Kontakt:
- Michael Weaver, MD
- E-Mail: MJWEAVER@BWH.HARVARD.EDU
-
Hauptermittler:
- Michael Weaver, MD
-
-
Mississippi
-
University, Mississippi, Vereinigte Staaten, 38677
- Rekrutierung
- University of Mississippi
-
Hauptermittler:
- Patrick Bergin, MD
-
Kontakt:
- Patrick Bergin, MD
- E-Mail: pbergin@umc.edu
-
-
New York
-
New York, New York, Vereinigte Staaten, 10016
- Rekrutierung
- NYU Langone Health
-
Hauptermittler:
- Ran Schwarzkopf, MD
-
Kontakt:
- Daniel Waren
- E-Mail: Daniel.waren@nyulangone.org
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten, 45221
- Rekrutierung
- University of Cincinnati
-
Kontakt:
- Michael Beltran, MD
- E-Mail: beltrame@ucmail.uc.edu
-
Hauptermittler:
- Michael Beltran, MD
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- Rekrutierung
- University of Oklahoma Health Sciences Center
-
Hauptermittler:
- Brandon Hull, MD
-
Kontakt:
- Brandon Hull, MD
- E-Mail: Brandon-Hull@ou.edu
-
-
Pennsylvania
-
Allentown, Pennsylvania, Vereinigte Staaten, 18102
- Rekrutierung
- St. Luke's University Health System
-
Hauptermittler:
- Dustin Greenhill, MD
-
Kontakt:
- Dustin Greenhill, MD
- E-Mail: dustin.greenhill@sluhn.org
-
-
South Carolina
-
Greenville, South Carolina, Vereinigte Staaten, 29601
- Rekrutierung
- Prisma Health-Upstate
-
Hauptermittler:
- Kyle Jeray, MD
-
Kontakt:
- Kyle Jeray, MD
- E-Mail: kyle.jeray@prismahealth.org
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten, 37235
- Rekrutierung
- Vanderbilt University
-
Kontakt:
- Lauren Tatman, MD
- E-Mail: lauren.m.tatman@vumc.org
-
Hauptermittler:
- Lauren Tatman, MD
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84108
- Rekrutierung
- University of Utah
-
Hauptermittler:
- Lucas Marchand, MD
-
Kontakt:
- Lucas Marchand, MD
- E-Mail: lucas.marchand@hsc.utah.edu
-
-
Vermont
-
Burlington, Vermont, Vereinigte Staaten, 05405
- Noch keine Rekrutierung
- University of Vermont
-
Kontakt:
- Michael Blankstein, MD
- E-Mail: michael.blankstein@uvmhealth.org
-
Hauptermittler:
- Michael Blankstein, MD
-
-
Virginia
-
Fairfax, Virginia, Vereinigte Staaten, 22031
- Rekrutierung
- Inova Health Care Services
-
Hauptermittler:
- Greg Gaski, MD
-
Kontakt:
- Grag Gaski, MD
- E-Mail: greg.gaski@inova.org
-
-
Wisconsin
-
Madison, Wisconsin, Vereinigte Staaten, 53706
- Rekrutierung
- University of Wisconsin - Madison
-
Hauptermittler:
- Chris Domes, MD
-
Kontakt:
- Chris Domes, MD
- E-Mail: domes@ortho.wisc.edu
-
-
-
-
-
Edinburgh, Vereinigtes Königreich, EH8 8BG
- Noch keine Rekrutierung
- University of Edinburgh
-
Kontakt:
- Andrew Duckworth, MD
- E-Mail: andrew.duckworth@ed.ac.uk
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- 60 years of age or older undergoing surgery due to a minimally displaced femoral neck fracture
- The patient has a health condition affecting physical mobility.
- Complete fracture of the femoral neck (AO/OTA 31B) confirmed with anteroposterior and lateral hip radiographs, computed tomography, or magnetic resonance imaging.
- Minimally displaced fracture that could be, in the judgment of the attending surgeon, managed with either arthroplasty or in situ internal fixation without reduction.
- Low energy injury mechanism.
- Surgeons with expertise in internal fixation and total hip arthroplasty or hemiarthroplasty are available to perform surgery.
Exclusion Criteria:
- The patient is not clinically suitable for either compared treatment.
- Expected injury survival of less than 12 months.
- Terminal illness with expected survival of less than 12 months.
- Incarceration.
- Unable to obtain informed consent due to language barriers.
- Unable to obtain informed consent because the legally authorized representative was unavailable.
- Problems, in the judgment of the study personnel, with maintaining follow-up with the patient.
- Currently enrolled in a study or intervention domain that does not permit co-enrollment.
- Prior enrollment in the specific platform trial intervention domain.
- Patient or legally authorized representative did not provide informed consent (declined participation).
- Eligible patient or legally authorized representative was not approached within the screening window (missed participant).
- Other reasons to exclude the patient, as approved by the data coordinating center.
- Associated lower extremity injury that prevents post-operative weight-bearing.
- Retained hardware around the hip that precludes either study treatment.
- Infection around the hip (soft tissue or bone).
- Pathologic fracture with a lytic lesion in the femoral neck that precludes internal fixation.
- Injury did not occur within 21 days of screening.
- Patient is too ill, in the judgment of the attending surgeon, for internal fixation.
- Patient is too ill, in the judgment of the attending surgeon, for arthroplasty.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Hüftarthroplastik
|
Participants will undergo surgical treatment using standard hip arthroplasty techniques for femoral minimally displaced femoral neck fracture. A modern porous-coated press-fit or cemented hip arthroplasty prosthesis will be used at the treating surgeon's discretion. Press-fit implants that have no ingrowth or ongrowth surface will not be permitted. The type of hip prosthesis (hemiarthroplasty or total hip arthroplasty), bearing (single or dual mobility), or the method of arthroplasty fixation (cemented or uncemented) will be at the discretion of the treating surgeon. |
|
Aktiver Komparator: Interne Fixierung
|
Participants will undergo surgical treatment using standard fixation techniques for minimally displaced femoral neck fractures. The treating surgeon may perform fracture reduction maneuvers if desired. Fixed-angle devices and multiple screws will be permitted. The internal fixation device(s) will be inserted through a small lateral incision. Internal fixation constructs combining cancellous screws and fixed-angle devices will be permitted. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Composite outcome of death, ambulation status, and days alive and out of hospital.
Zeitfenster: 120 days after randomization
|
Death consists of time to all-cause mortality. Ambulation will be evaluated using an ordinal ranking of independence. Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:
|
120 days after randomization
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Composite outcome of death, ambulation status, and days alive and out of hospital.
Zeitfenster: 365 days after randomization
|
Death consists of time to all-cause mortality. Ambulation will be evaluated using an ordinal ranking of independence. Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:
|
365 days after randomization
|
|
Death
Zeitfenster: 120 days post-randomization
|
Death consists of time to all-cause mortality. |
120 days post-randomization
|
|
Death
Zeitfenster: 12 months post-randomization
|
Death consists of time to all-cause mortality. |
12 months post-randomization
|
|
Ambulation status
Zeitfenster: 120 days post-randomization
|
Ambulation will be evaluated using an ordinal ranking of independence |
120 days post-randomization
|
|
Ambulation status
Zeitfenster: 12 months post-randomization
|
Ambulation will be evaluated using an ordinal ranking of independence |
12 months post-randomization
|
|
Days alive and out of hospital
Zeitfenster: 120 days post-randomization
|
Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:
|
120 days post-randomization
|
|
Days alive and out of hospital
Zeitfenster: 12 months post-randomization
|
Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below:
|
12 months post-randomization
|
|
Health-related quality of life
Zeitfenster: 120 days days post-randomization
|
EQ-5D-5L - Range: 0 to 1, Higher scores indicates better self-perceived health |
120 days days post-randomization
|
|
Health-related quality of life
Zeitfenster: 12 months post-randomization
|
EQ-5D-5L - Range: 0 to 1, Higher scores indicates better self-perceived health |
12 months post-randomization
|
|
Numeric Pain Rating Scale
Zeitfenster: During hospitalization in the first seven postoperative days
|
The highest level of pain recorded daily in the participant's medical record - Range: 0-10, higher score indicates higher level of pain |
During hospitalization in the first seven postoperative days
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Hauptermittler: Joseph T Patterson, MD, University of Southern California
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Wunden und Verletzungen
- Beinverletzungen
- Frakturen, Knochen
- Hüftverletzungen
- Femurfrakturen
- Hüftfrakturen
- Schenkelhalsfrakturen
- Therapeutika
- Chirurgische Eingriffe, operativ
- Arthroplastik, Ersatz
- Arthroplastik
- Orthopädische Verfahren
- Plastische Eingriffe
- Protheseimplantation
- Frakturfixierung
- Arthroplastik, Ersatz, Hüfte
- Frakturfixierung, intern
Andere Studien-ID-Nummern
- BPS-2024C1-37436
- BPS-2024C1-37436 (Andere Zuschuss-/Finanzierungsnummer: Patient-Centered Outcomes Research Institute)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .